Australia markets open in 6 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2562-0.0438 (-14.60%)
At close: 04:00PM EDT
0.2535 -0.00 (-1.05%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3000
Open0.2740
Bid0.2500 x 800
Ask0.2535 x 4000
Day's range0.2510 - 0.2881
52-week range0.2260 - 1.5800
Volume2,524,146
Avg. volume4,810,569
Market cap10.278M
Beta (5Y monthly)0.74
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Patient Experience Survey Reported Positive Findings for GIMOTI®

    Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTISOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from the first patient-centered survey related to GIMOTI. Following the series of market

  • GlobeNewswire

    Evoke Pharma to Present at H.C. Wainwright Global Investment Conference

    SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that its management team will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022. The presentation will be virtual and will provide an overview of the comm

  • GlobeNewswire

    Evoke Pharma Reports First Quarter 2022 Financial Results

    Several sales growth indicators increased over Q4, 2021: New Prescribers up 41%; Product delivered to patients up 39%; Net Revenue increased by 16%; Prescriptions written up 22%SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2022, and recent corporate developments. “We are encou